Month: September 2026

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy (MSA).

MSA is a rare, rapidly progressive neurodegenerative disorder that affects autonomic functions (such as blood pressure and bladder control) and motor control, leading to severe disability and shortened life expectancy. There are currently no FDA-approved disease-modifying therapies for MSA. The disease has a mean incidence in the U.S. of approximately 0.6 per 100,000 person-years, rising to about 3 per 100,000 in those aged 50 and older, with prevalence estimates of roughly 1.9–4.9 per 100,000 worldwide. Median survival is typically 6–9 years. Neuroinflammation and microglial activation are increasingly recognized as key contributors to MSA pathogenesis.

Orphan Drug Designation is granted by the FDA to drugs or biologics intended to treat rare diseases or conditions affecting fewer than 200,000 people in the United States. The FDA’s Office of Orphan Products Development (OOPD) aims to complete its review of an orphan drug designation (ODD) request within 90 days of receipt. If granted, the designation would provide potential benefits including seven years of market exclusivity upon approval, tax credits for qualified clinical testing, waiver of certain FDA application fees, and eligibility for protocol assistance.

Tiziana is currently evaluating intranasal foralumab in a Phase 2a open-label clinical trial (ClinicalTrials.gov Identifier: NCT06868628) in patients with MSA. The six-month study is designed to assess effects on microglial activation (via PET imaging), clinical outcomes, and safety. Foralumab is administered via nasal spray across eight 3-week dosing cycles. The Phase 2a trial is being conducted within the MyTrial Program at Brigham and Women’s Hospital in Boston under the leadership of Principal Investigator Vikram Khurana, MD, PhD, Tracy T. Batchelor Endowed Chair and Division Chief of Movement Disorders at Mass General Brigham.

Dr Khurana commented: “Multiple system atrophy remains one of the most challenging neurodegenerative diseases we face, with rapid progression and no approved therapies that alter its course. The growing recognition of neuroinflammation and microglial activation as central drivers of MSA pathology makes intranasal foralumab a particularly compelling candidate. By harnessing the immune system’s regulatory pathways in a targeted, non-systemic way, this approach has the potential to address a critical unmet need. The ongoing clinical study, which includes PET imaging of microglial activity, will provide important early insights into whether this strategy can meaningfully impact the disease process.”

Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented: “Filing for Orphan Drug Designation for intranasal foralumab in MSA represents an important regulatory step as we advance this novel therapy for patients facing a devastating disease with no approved disease-modifying options. Foralumab administered intranasally induces regulatory T cells and modulates T-cell-driven inflammation. Its ability to reduce microglial activation offers a promising strategy to slow neuronal damage in neuroinflammatory and neurodegenerative conditions including MSA. This non-systemic approach is designed to promote immune tolerance while minimizing systemic immune suppression.”

About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923), as well as additional Phase 2 trials in AD and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and include statements regarding the closing of the Offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — Enigmatig Limited (NYSE American: EGG) (“Enigmatig” or the “Company”), a global business enabler supporting companies expanding across borders, today announced that the Company issued the following statement in accordance with Section 401(d) of the NYSE American Company Guide regarding recent trading activity in its ordinary shares on September 28 and September 29, 2026.

The Company’s general policy is not to comment on unusual market activity or market speculation. The Company confirms that, based on its internal review, it is not aware of any material developments in its business or affairs that have not been previously disclosed, nor is it aware of any other reason that would account for the recent unusual market activity in the Company’s ordinary shares.

The Company will continue to comply with its disclosure obligations applicable under federal securities laws and the NYSE American Company Guide.

About Enigmatig Limited
Enigmatig is a global business enabler supporting companies in achieving their international ambitions. Since 2010, we have provided expertise, infrastructure, and regulatory guidance to help businesses operate and scale across borders.

With capabilities spanning licensing, fintech, regtech and other corporate services, Enigmatig delivers tailored solutions across the business lifecycle — from incorporation to ongoing compliance. Our team navigates complex regulatory environments across major financial hubs and key offshore centers, including London, Cyprus, and Belize.

Headquartered in Singapore, with a presence in Bangkok, Hong Kong, Jakarta, Shanghai, London, Taipei and Tokyo, Enigmatig serves a diverse and growing international client base.

For more information, please visit: https://enigmatig.com

Safe Harbor Statement
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “aim,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “is/are likely to,” “potential,” “project” or “continue” or the negative of these terms or other comparable or similar terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries, please contact:
Enigmatig Investors Relations
investors@enigmatig.com / cindy@enigmatig.com

SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — Enigmatig Limited (NYSE American: EGG) (“Enigmatig” or the “Company”), a global business enabler supporting companies expanding across borders, today announced that the Company issued the following statement in accordance with Section 401(d) of the NYSE American Company Guide regarding recent trading activity in its ordinary shares on September 28 and September 29, 2026.

The Company’s general policy is not to comment on unusual market activity or market speculation. The Company confirms that, based on its internal review, it is not aware of any material developments in its business or affairs that have not been previously disclosed, nor is it aware of any other reason that would account for the recent unusual market activity in the Company’s ordinary shares.

The Company will continue to comply with its disclosure obligations applicable under federal securities laws and the NYSE American Company Guide.

About Enigmatig Limited
Enigmatig is a global business enabler supporting companies in achieving their international ambitions. Since 2010, we have provided expertise, infrastructure, and regulatory guidance to help businesses operate and scale across borders.

With capabilities spanning licensing, fintech, regtech and other corporate services, Enigmatig delivers tailored solutions across the business lifecycle — from incorporation to ongoing compliance. Our team navigates complex regulatory environments across major financial hubs and key offshore centers, including London, Cyprus, and Belize.

Headquartered in Singapore, with a presence in Bangkok, Hong Kong, Jakarta, Shanghai, London, Taipei and Tokyo, Enigmatig serves a diverse and growing international client base.

For more information, please visit: https://enigmatig.com

Safe Harbor Statement
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “aim,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “is/are likely to,” “potential,” “project” or “continue” or the negative of these terms or other comparable or similar terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries, please contact:
Enigmatig Investors Relations
investors@enigmatig.com / cindy@enigmatig.com

LIMASSOL, Cyprus, Sept. 30, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), today announced the final results of the previously announced tender offer by the Company to purchase for cash up to $20,000,000 in value of its ordinary shares, no par value per ordinary share (each, a “share”), or up to 1,813,236 shares, at a purchase price of $11.03 per share, net to the seller in cash, without interest, less any applicable withholding taxes, which expired at 5:00 p.m., Eastern Time, on September 28, 2026.

Based on the final count by Continental Stock Transfer & Trust Company, the depositary for the tender offer (the “Depositary”), 57,110 shares were properly tendered and not properly withdrawn.

In accordance with the terms and conditions of the tender offer, and based on the final results reported by the Depositary, the Company has accepted for purchase 57,110 shares through the tender offer at a price of $11.03 per share, for an aggregate cost of approximately $629.9 thousand, excluding fees relating to the tender offer. The number of shares that the Company has accepted for purchase in the tender offer represents approximately 0.3% of the total number of issued ordinary shares of the Company outstanding as of the commencement of the tender offer on August 31, 2026.

The Company will have approximately 18.1 million shares outstanding immediately following payment for the shares purchased in the tender offer. The shares acquired pursuant to the tender offer will be held by the Company as treasury shares, and will remain available for the Company to issue in the future.

The Depositary will promptly pay for all of the shares accepted for purchase, and all shares not accepted for purchase will be returned to shareholders, in each case, in accordance with the terms and conditions of the tender offer.

D.F. King & Co., Inc. is serving as the information agent for the tender offer, and Continental Stock Transfer & Trust Company is serving as the Depositary. For all questions regarding the tender offer, please contact the information agent, D.F. King & Co., Inc., by calling +1 (800) 549-6864, or by emailing gdev@dfking.com.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc.

Certain information regarding the tender offer

The information in this press release describing GDEV Inc.’s tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of GDEV Inc. in the tender offer. The tender offer will only be made pursuant to the Offer to Purchase, the related Letter of Transmittal and other related materials filed as part of the Tender Offer Statement on Schedule TO, in each case as may be amended or supplemented from time to time. Shareholders should read such Offer to Purchase and related materials carefully and in their entirety because they contain important information, including the various terms and conditions of the tender offer.

Shareholders of GDEV Inc. may obtain a free copy of the Tender Offer Statement on Schedule TO, the Offer to Purchase and other documents that GDEV Inc. is filing with the Securities and Exchange Commission from the Securities and Exchange Commission’s website at www.sec.gov. Shareholders may also obtain a copy of these documents, without charge, from D.F. King & Co., Inc., the information agent for the tender offer, by calling (800) 549-6864 (U.S. toll‑free), or by emailing gdev@dfking.com. Shareholders are urged to carefully read all of these materials prior to making any decision with respect to the tender offer. Shareholders and investors who have questions or need assistance may call D.F. King & Co., Inc., the information agent for the tender offer, toll free at (800) 549-6864, or may email D.F. King & Co., Inc. at gdev@dfking.com.

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2025 Annual Report on Form 20-F, filed by the Company on March 31, 2026, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

LIMASSOL, Cyprus, Sept. 30, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), today announced the final results of the previously announced tender offer by the Company to purchase for cash up to $20,000,000 in value of its ordinary shares, no par value per ordinary share (each, a “share”), or up to 1,813,236 shares, at a purchase price of $11.03 per share, net to the seller in cash, without interest, less any applicable withholding taxes, which expired at 5:00 p.m., Eastern Time, on September 28, 2026.

Based on the final count by Continental Stock Transfer & Trust Company, the depositary for the tender offer (the “Depositary”), 57,110 shares were properly tendered and not properly withdrawn.

In accordance with the terms and conditions of the tender offer, and based on the final results reported by the Depositary, the Company has accepted for purchase 57,110 shares through the tender offer at a price of $11.03 per share, for an aggregate cost of approximately $629.9 thousand, excluding fees relating to the tender offer. The number of shares that the Company has accepted for purchase in the tender offer represents approximately 0.3% of the total number of issued ordinary shares of the Company outstanding as of the commencement of the tender offer on August 31, 2026.

The Company will have approximately 18.1 million shares outstanding immediately following payment for the shares purchased in the tender offer. The shares acquired pursuant to the tender offer will be held by the Company as treasury shares, and will remain available for the Company to issue in the future.

The Depositary will promptly pay for all of the shares accepted for purchase, and all shares not accepted for purchase will be returned to shareholders, in each case, in accordance with the terms and conditions of the tender offer.

D.F. King & Co., Inc. is serving as the information agent for the tender offer, and Continental Stock Transfer & Trust Company is serving as the Depositary. For all questions regarding the tender offer, please contact the information agent, D.F. King & Co., Inc., by calling +1 (800) 549-6864, or by emailing gdev@dfking.com.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc.

Certain information regarding the tender offer

The information in this press release describing GDEV Inc.’s tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of GDEV Inc. in the tender offer. The tender offer will only be made pursuant to the Offer to Purchase, the related Letter of Transmittal and other related materials filed as part of the Tender Offer Statement on Schedule TO, in each case as may be amended or supplemented from time to time. Shareholders should read such Offer to Purchase and related materials carefully and in their entirety because they contain important information, including the various terms and conditions of the tender offer.

Shareholders of GDEV Inc. may obtain a free copy of the Tender Offer Statement on Schedule TO, the Offer to Purchase and other documents that GDEV Inc. is filing with the Securities and Exchange Commission from the Securities and Exchange Commission’s website at www.sec.gov. Shareholders may also obtain a copy of these documents, without charge, from D.F. King & Co., Inc., the information agent for the tender offer, by calling (800) 549-6864 (U.S. toll‑free), or by emailing gdev@dfking.com. Shareholders are urged to carefully read all of these materials prior to making any decision with respect to the tender offer. Shareholders and investors who have questions or need assistance may call D.F. King & Co., Inc., the information agent for the tender offer, toll free at (800) 549-6864, or may email D.F. King & Co., Inc. at gdev@dfking.com.

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2025 Annual Report on Form 20-F, filed by the Company on March 31, 2026, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Portable solution combines 2D/3D live broadcasting, real-time interpretation in 65+ languages, recording and AI-powered Knowledge Capture, with post-event 2D-to-3D conversion and AI course generation

Key Facts At-a-Glance

One case. One event. A complete AI-powered hybrid experience. HybriU Events brings 2D or 3D live broadcasting, real-time interpretation in 65+ languages, professional recording, remote participation and AI-powered Knowledge Capture to conferences, ceremonies, meetings and live programs. It is delivered on demand in a single portable system, without requiring permanent installation or equipment purchase. After the event, captured content can continue to create value through searchable AI knowledge, automated course generation and optional 2D-to-3D conversion.

Available now for event bookings in North America, with pricing based on event requirements.

CUPERTINO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO), an AI-driven technology company delivering phygital intelligence solutions for education, enterprise collaboration and live events, today announced the on-demand availability of HybriU Events, a portable event solution delivered to an organizer’s venue in a single transport case.

Caption: The HybriU Events transport case, closed for transport and opened for deployment. Ambow delivers and operates the system at the organizer’s venue.

Alt text: The HybriU Events transport case, shown closed on wheels for transport and opened for deployment with its PTZ camera mounted on a tripod.

Designed for conferences, ceremonies, annual meetings, training programs, cultural events and other live gatherings, HybriU Events enables organizers to add professional live broadcasting, multilingual participation, remote engagement, recording and AI-powered knowledge capture without purchasing dedicated equipment or permanently modifying the venue.

The portable system brings together cameras, capture and processing hardware, AI capabilities and broadcast technology in a transportable configuration operated by Ambow. It can be brought into a venue for an event and removed afterward, allowing organizations to access advanced event technology when they need it rather than maintaining permanent infrastructure.

HybriU Events supports both conventional 2D and immersive 3D live broadcasting, allowing organizers to select the format best suited to each event and audience.

“Most organizations do not need to own an entire event technology infrastructure just to make one or two important events each year more accessible, intelligent and reusable,” said Dr. Jin Huang, Chief Executive Officer and Chair of the Board of Ambow Education Holding Ltd. “HybriU Events brings the technology to them. We can capture the event, broadcast it, connect people across languages and locations, and turn what happens during those few hours into knowledge and digital assets that can continue to create value long after the event is over.”

One Portable System for the Entire Event

Traditional event production can require separate providers for video recording, live streaming, interpretation, remote participation and post-event content production. HybriU Events brings these capabilities together through a single portable service.

• 2D or 3D live broadcasting, giving organizers the flexibility to deliver conventional or immersive viewing experiences;
• Live streaming and remote participation, extending an event beyond the physical venue to online audiences;
• Real-time interpretation in 65+ languages through WeSpeak, allowing on-site and remote participants to follow event content in their preferred language;
• Professional event recording, capturing presentations, discussions and other event content without requiring a separate recording workflow;
• Interactive audience engagement, connecting physical and remote participants within the same event experience; and
• AI-powered Knowledge Capture, transforming event content into transcripts, summaries, searchable knowledge, highlights and reusable digital assets.

Rather than treating broadcasting, interpretation, recording and AI processing as separate workflows, HybriU Events brings them together within one service.

The Event Ends. Its Value Does Not.

HybriU Events is designed not only to expand the reach of an event while it is happening, but also to preserve and activate the knowledge created during it.

After an event, HybriU can process recorded presentations, discussions and sessions into structured, searchable knowledge. Instead of leaving organizers with hours of raw video, the platform can generate transcripts, summaries, key insights, highlights and reusable digital content.

Through HybriU’s AI course generation capabilities, selected event content can also be transformed into structured learning experiences. A two-day conference can become an on-demand training program. A professional seminar can become reusable learning content. A university symposium can become a searchable knowledge library. An annual meeting can become a structured record of presentations, discussions and insights.

The result is a shift from an event as a temporary experience to an event as a reusable knowledge asset.

From 2D Today to 3D Tomorrow

Organizations do not need to produce an entire event in 3D to take advantage of immersive content.

As an optional post-event service, HybriU can convert selected 2D event recordings and other digital content into 3D experiences. Organizers can therefore broadcast an event conventionally in 2D and later identify high-value presentations, performances or other content for 3D conversion.

This approach gives organizations the flexibility to adopt immersive content selectively, without requiring a 3D-first production model.

Designed for On-Demand Deployment

The portable architecture is designed to minimize dependence on permanent venue infrastructure.

The HybriU Events transport case contains the core capture, processing and AI technology required for the service. Ambow delivers and operates the system for the event and removes it afterward.

This makes HybriU Events suitable for hotel ballrooms, conference centers, university facilities, corporate meeting spaces, cultural venues and other locations where permanent installation may be unnecessary or impractical.

Organizations can access advanced event capabilities without purchasing and maintaining dedicated equipment or committing to a recurring subscription.

“HybriU is becoming an intelligence layer connecting physical environments, AI, digital systems and institutional knowledge,” said Dr. Huang. “Events are a natural extension of that strategy because an enormous amount of valuable knowledge is created through live interaction and then lost. HybriU Events gives organizations a practical way to capture that activity, connect people across locations and languages, and turn temporary experiences into reusable knowledge.”

Availability

HybriU Events is available now for event bookings, initially in North America.

Event organizers, associations, conference producers, universities, enterprises and venues can request availability, pricing and demonstrations at www.hybriu.com.

About Ambow Education Holding Ltd.

Ambow Education Holding Ltd. (NYSE American: AMBO) is an AI-driven technology company delivering phygital intelligence solutions for education, enterprise collaboration and live events.

Founded in 2000 and headquartered in Cupertino, California, Ambow develops technologies that connect physical environments, artificial intelligence, digital systems, workflows and institutional knowledge.

Through HybriU, Ambow enables institutions and professionals to capture, organize, activate and reuse knowledge generated across classrooms, meetings and events, creating intelligence assets that can become more valuable over time.

HybriU: www.hybriu.com

Follow Ambow on X: @Ambow_Education

Follow Ambow on LinkedIn: Ambow Education Group

Contact Information

Ambow Education Holding Ltd.

E-mail: ir@ambow.com

Forward-Looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “will,” “expects,” “believes,” “anticipates,” “intends,” “estimates” and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Ambow and the industry. All information provided in this press release is as of the date hereof, and Ambow undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although Ambow believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

Portable solution combines 2D/3D live broadcasting, real-time interpretation in 65+ languages, recording and AI-powered Knowledge Capture, with post-event 2D-to-3D conversion and AI course generation

Key Facts At-a-Glance

One case. One event. A complete AI-powered hybrid experience. HybriU Events brings 2D or 3D live broadcasting, real-time interpretation in 65+ languages, professional recording, remote participation and AI-powered Knowledge Capture to conferences, ceremonies, meetings and live programs. It is delivered on demand in a single portable system, without requiring permanent installation or equipment purchase. After the event, captured content can continue to create value through searchable AI knowledge, automated course generation and optional 2D-to-3D conversion.

Available now for event bookings in North America, with pricing based on event requirements.

CUPERTINO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO), an AI-driven technology company delivering phygital intelligence solutions for education, enterprise collaboration and live events, today announced the on-demand availability of HybriU Events, a portable event solution delivered to an organizer’s venue in a single transport case.

Caption: The HybriU Events transport case, closed for transport and opened for deployment. Ambow delivers and operates the system at the organizer’s venue.

Alt text: The HybriU Events transport case, shown closed on wheels for transport and opened for deployment with its PTZ camera mounted on a tripod.

Designed for conferences, ceremonies, annual meetings, training programs, cultural events and other live gatherings, HybriU Events enables organizers to add professional live broadcasting, multilingual participation, remote engagement, recording and AI-powered knowledge capture without purchasing dedicated equipment or permanently modifying the venue.

The portable system brings together cameras, capture and processing hardware, AI capabilities and broadcast technology in a transportable configuration operated by Ambow. It can be brought into a venue for an event and removed afterward, allowing organizations to access advanced event technology when they need it rather than maintaining permanent infrastructure.

HybriU Events supports both conventional 2D and immersive 3D live broadcasting, allowing organizers to select the format best suited to each event and audience.

“Most organizations do not need to own an entire event technology infrastructure just to make one or two important events each year more accessible, intelligent and reusable,” said Dr. Jin Huang, Chief Executive Officer and Chair of the Board of Ambow Education Holding Ltd. “HybriU Events brings the technology to them. We can capture the event, broadcast it, connect people across languages and locations, and turn what happens during those few hours into knowledge and digital assets that can continue to create value long after the event is over.”

One Portable System for the Entire Event

Traditional event production can require separate providers for video recording, live streaming, interpretation, remote participation and post-event content production. HybriU Events brings these capabilities together through a single portable service.

• 2D or 3D live broadcasting, giving organizers the flexibility to deliver conventional or immersive viewing experiences;
• Live streaming and remote participation, extending an event beyond the physical venue to online audiences;
• Real-time interpretation in 65+ languages through WeSpeak, allowing on-site and remote participants to follow event content in their preferred language;
• Professional event recording, capturing presentations, discussions and other event content without requiring a separate recording workflow;
• Interactive audience engagement, connecting physical and remote participants within the same event experience; and
• AI-powered Knowledge Capture, transforming event content into transcripts, summaries, searchable knowledge, highlights and reusable digital assets.

Rather than treating broadcasting, interpretation, recording and AI processing as separate workflows, HybriU Events brings them together within one service.

The Event Ends. Its Value Does Not.

HybriU Events is designed not only to expand the reach of an event while it is happening, but also to preserve and activate the knowledge created during it.

After an event, HybriU can process recorded presentations, discussions and sessions into structured, searchable knowledge. Instead of leaving organizers with hours of raw video, the platform can generate transcripts, summaries, key insights, highlights and reusable digital content.

Through HybriU’s AI course generation capabilities, selected event content can also be transformed into structured learning experiences. A two-day conference can become an on-demand training program. A professional seminar can become reusable learning content. A university symposium can become a searchable knowledge library. An annual meeting can become a structured record of presentations, discussions and insights.

The result is a shift from an event as a temporary experience to an event as a reusable knowledge asset.

From 2D Today to 3D Tomorrow

Organizations do not need to produce an entire event in 3D to take advantage of immersive content.

As an optional post-event service, HybriU can convert selected 2D event recordings and other digital content into 3D experiences. Organizers can therefore broadcast an event conventionally in 2D and later identify high-value presentations, performances or other content for 3D conversion.

This approach gives organizations the flexibility to adopt immersive content selectively, without requiring a 3D-first production model.

Designed for On-Demand Deployment

The portable architecture is designed to minimize dependence on permanent venue infrastructure.

The HybriU Events transport case contains the core capture, processing and AI technology required for the service. Ambow delivers and operates the system for the event and removes it afterward.

This makes HybriU Events suitable for hotel ballrooms, conference centers, university facilities, corporate meeting spaces, cultural venues and other locations where permanent installation may be unnecessary or impractical.

Organizations can access advanced event capabilities without purchasing and maintaining dedicated equipment or committing to a recurring subscription.

“HybriU is becoming an intelligence layer connecting physical environments, AI, digital systems and institutional knowledge,” said Dr. Huang. “Events are a natural extension of that strategy because an enormous amount of valuable knowledge is created through live interaction and then lost. HybriU Events gives organizations a practical way to capture that activity, connect people across locations and languages, and turn temporary experiences into reusable knowledge.”

Availability

HybriU Events is available now for event bookings, initially in North America.

Event organizers, associations, conference producers, universities, enterprises and venues can request availability, pricing and demonstrations at www.hybriu.com.

About Ambow Education Holding Ltd.

Ambow Education Holding Ltd. (NYSE American: AMBO) is an AI-driven technology company delivering phygital intelligence solutions for education, enterprise collaboration and live events.

Founded in 2000 and headquartered in Cupertino, California, Ambow develops technologies that connect physical environments, artificial intelligence, digital systems, workflows and institutional knowledge.

Through HybriU, Ambow enables institutions and professionals to capture, organize, activate and reuse knowledge generated across classrooms, meetings and events, creating intelligence assets that can become more valuable over time.

HybriU: www.hybriu.com

Follow Ambow on X: @Ambow_Education

Follow Ambow on LinkedIn: Ambow Education Group

Contact Information

Ambow Education Holding Ltd.

E-mail: ir@ambow.com

Forward-Looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “will,” “expects,” “believes,” “anticipates,” “intends,” “estimates” and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Ambow and the industry. All information provided in this press release is as of the date hereof, and Ambow undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although Ambow believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

FREMONT, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced that its operating subsidiary, ACM Research (Shanghai), Inc. (“ACM Shanghai”) posted backlog figures for ACM Shanghai as of September 29, 2026 on the Shanghai Stock Exchange website [link to China Disclosure].

Backlog

As of September 29, 2026, ACM Shanghai’s total backlog amounted to RMB 17.1 billion (USD $2.5 billion), an 88.2% year-over-year increase compared with the prior year’s disclosed backlog. The total backlog figures include a mix of orders for tools that have been shipped but not yet recognized as revenue under Chinese generally accepted accounting principles (“Chinese GAAP”), and orders for tools expected to be shipped at a future date.

Backlog is not a financial measure that is defined or recognized by Chinese GAAP or U.S. generally accepted accounting principles, and ACM Shanghai’s method for determining and calculating backlog, and the underlying assumptions, may not be comparable to the methodologies and assumptions used by other companies. Orders included in backlog may not actually generate the amounts of revenue estimated above.

All USD amounts above are for reference only and are translated using the September 29, 2026 Wall Street Journal closing exchange rate.

Reporting Dates

ACM Shanghai will release its full financial results for the nine months ended September 30, 2026 on October 28, 2026 after the market close in China, and on the same day ACM will report preliminary financial results for the nine months ended September 30, 2026 before the market open in the U.S.

ACM will release its full financial results for the third quarter of 2026 and conduct a corresponding conference call to discuss the results in early November 2026. The specific reporting date and details of the conference call will be released at a later date.

Forward-Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on ACM management’s current expectations and beliefs and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings ACM makes with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by ACM. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ACM undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

About ACM Research, Inc.

ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com.

© ACM Research, Inc. ACM Research logo is a trademark of ACM Research, Inc. For convenience, these trademarks appear in this press release without ™ symbols, but that practice does not mean ACM will not assert, to the fullest extent under applicable law, its rights to such trademarks. All other trademarks are the property of their respective owners.

For investor and media inquiries, please contact:

In the United States:	The Blueshirt Group Steven C. Pelayo, CFA +1 (360) 808-5154 steven@blueshirtgroup.co
In China:	The Blueshirt Group Asia Gary Dvorchak, CFA gary@blueshirtgroup.co

FREMONT, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced that its operating subsidiary, ACM Research (Shanghai), Inc. (“ACM Shanghai”) posted backlog figures for ACM Shanghai as of September 29, 2026 on the Shanghai Stock Exchange website [link to China Disclosure].

Backlog

As of September 29, 2026, ACM Shanghai’s total backlog amounted to RMB 17.1 billion (USD $2.5 billion), an 88.2% year-over-year increase compared with the prior year’s disclosed backlog. The total backlog figures include a mix of orders for tools that have been shipped but not yet recognized as revenue under Chinese generally accepted accounting principles (“Chinese GAAP”), and orders for tools expected to be shipped at a future date.

Backlog is not a financial measure that is defined or recognized by Chinese GAAP or U.S. generally accepted accounting principles, and ACM Shanghai’s method for determining and calculating backlog, and the underlying assumptions, may not be comparable to the methodologies and assumptions used by other companies. Orders included in backlog may not actually generate the amounts of revenue estimated above.

All USD amounts above are for reference only and are translated using the September 29, 2026 Wall Street Journal closing exchange rate.

Reporting Dates

ACM Shanghai will release its full financial results for the nine months ended September 30, 2026 on October 28, 2026 after the market close in China, and on the same day ACM will report preliminary financial results for the nine months ended September 30, 2026 before the market open in the U.S.

ACM will release its full financial results for the third quarter of 2026 and conduct a corresponding conference call to discuss the results in early November 2026. The specific reporting date and details of the conference call will be released at a later date.

Forward-Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on ACM management’s current expectations and beliefs and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings ACM makes with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by ACM. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ACM undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

About ACM Research, Inc.

ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com.

© ACM Research, Inc. ACM Research logo is a trademark of ACM Research, Inc. For convenience, these trademarks appear in this press release without ™ symbols, but that practice does not mean ACM will not assert, to the fullest extent under applicable law, its rights to such trademarks. All other trademarks are the property of their respective owners.

For investor and media inquiries, please contact:

In the United States:	The Blueshirt Group Steven C. Pelayo, CFA +1 (360) 808-5154 steven@blueshirtgroup.co
In China:	The Blueshirt Group Asia Gary Dvorchak, CFA gary@blueshirtgroup.co

SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) — Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology.

“We are pleased to welcome Chris to Adlai Nortye,” said Carsten Lu, Chairman and Chief Executive Officer of Adlai Nortye. “His deep understanding of oncology and extensive experience in the healthcare capital markets will be valuable as we continue to strengthen our engagement with the global investment community, enhance our external communications, and advance our pipeline.”

Dr. Liu added, “I am excited to join Adlai Nortye at this important stage of the Company’s development. I look forward to working with the team to deepen engagement with investors and other key stakeholders, and to effectively communicate the Company’s strategy, progress, and long-term value.”

About Christopher Liu, PharmD

Dr. Liu is an experienced equity research analyst with nearly a decade of experience analyzing biotechnology companies. He most recently served as a Managing Director of equity research at Lucid Capital Markets, where he covered biotechnology and oncology companies. Previously, he was a Director of equity research at Leerink Partners, focused on oncology equity research. He has also held biotechnology research roles at Canaccord Genuity and Oppenheimer & Co. Dr. Liu received his Doctor of Pharmacy (PharmD) degree from the Ernest Mario School of Pharmacy at Rutgers University.

About Adlai Nortye

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas:

1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.

2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells.   

Forward-Looking and Cautionary Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.

The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contacts:

Investor Relations:

ir@adlainortye.com